Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Vincenza CaputoVincenzo De FalcoAnna VentrigliaVincenzo FamigliettiErika MartinelliFloriana MorgilloGiulia MartiniCarminia Maria Della CorteDavide CiardielloLuca PolieroFerdinando De VitaMichele OrdituraMorena FasanoRenato FrancoMichele CaragliaArianna AvitabileRoberto ScalamognaBeatrice MarchiFortunato CiardielloTeresa TroianiStefania NapolitanoPublished in: Therapeutic advances in medical oncology (2022)
Although additional studies are needed to better select patients and setting, NGS F1LA is a useful, noninvasive, and repeatable assay to guide therapeutic choice in oncology. It provides a snapshot of cancer heterogeneity profile that could be incorporated in routinely clinical practice.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- end stage renal disease
- clinical practice
- chronic kidney disease
- ejection fraction
- single cell
- newly diagnosed
- papillary thyroid
- peritoneal dialysis
- high throughput
- squamous cell carcinoma
- gene expression
- genome wide
- patient reported outcomes
- squamous cell
- young adults
- childhood cancer